SUPERIORITY OF ENDOCARDIAL VERSUS EPICARDIAL IMPLANTATION OF THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)

被引：8

作者：

SAGGAU, W

SACK, FU

LANGE, R

WERLING, C

DESIMONE, R

BRACHMANN, J

HAGL, S

机构：

[1] Department of Cardiac Surgery, University of Heidelberg, Heidelberg

[2] Department of Cardiology, University of Heidelberg, Heidelberg

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1992年 / 6卷 / 04期

关键词：

IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; EPICARDIAL LEAD SYSTEM; ENDOCARDIAL LEAD SYSTEM; TRANSVENOUS APPROACH; MEDIAN STERNOTOMY; SUDDEN CARDIAC DEATH;

D O I：

10.1016/1010-7940(92)90216-K

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The implantable cardioverter-defibrillator (ICD) has proved to be an efficient device for the treatment of severe ventricular tachyarrhythmias (VT). From May 1985 to August 1991, the ICD was implanted in 107 patients of whom 72% suffered from coronary artery disease, 17% from cardiomyopathy, 5% from long QT-syndrome and 6% from other heart disease. All patients had a life threatening episode of VT or at least one episode of ventricular fibrillation. Of 107 implants, 12% were combined with other heart surgery, 55% were isolated epicardial implantations (epi I) and in 33%, the novel endocardial (endo I) approach was chosen. Between epi I and endo I we found no difference in operation time, but time for ICU and in-hospital stay was significantly shorter using the transvenous approach. In addition, sensing and pacing capability of the, endocardial screw-in electrode was superior and the need for thoracotomy was avoided, a particular advantage in patients with previous heart surgery. Complications after epi I were: temporary low cardiac output, 1; perioperative death, 2; infection, 3, and alter endo I: electrode dislocation, 2. Hence, endo I may become the method of choice for patients without concomitant surgery.

引用

页码：195 / 200

页数：6

共 35 条

[1]

Almassi G.H., Olinger G.N., Troup P.J., Delayed infection of the automatic implantable cardioverter defibrillator. Current recognition and management, J Thorac Cardiovasc Surg, 95, pp. 908-911, (1988)

[2]

Beck C.S., Pritchard W., Feil H.S., Ventricular fibrillation of long duration abolished by electrical Shock, JAMA, 135, pp. 985-986, (1947)

[3]

Blakeman B.M., Wiber D., Pifarre R., Median sternotomy for implantable cardioverter-defibrillator, Arch Surg, 124, pp. 1065-1066, (1989)

[4]

Borbola J., Denes P., Ezri M.D., The automatic implantable cardioverter defibrillator: Clinical experience, complications, and follow up in 25 patients, Arch Int Med, 148, pp. 70-76, (1988)

[5]

Cannom D., Winkle R., Implantation of the automatic implantable cardioverter defibrillator (AICD): Practical aspects, Pace, 9, pp. 793-805, (1986)

[6]

Echt D.S., Armstrong K., Schmid P., Oyer P., Stinson E., Winkle R.A., Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator, Circulation, 71, pp. 289-296, (1985)

[7]

Fosoros R.N., Elson J.J., Bonnet C.A., Fiedler S.B., Burkholder J.A., Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease, J Am Coll Cardiol, 16, pp. 381-386, (1990)

[8]

Garan H., Ruskin J.N., Di Marco J.P., Electrophysiologic studies before and after myocardial revascularization in patients with life-threatening ventricular arrhythmias, Am J Cardiol, 51, pp. 519-524, (1983)

[9]

Hamer A.W., Finerman W.B., Peter T., Mandel W.J., Disparity between the clinical and electrophysiologic effects of amidarone in the treatment of recurrent ventricular tachycardia, Am Heart J, 102, pp. 992-1000, (1981)

[10]

Kelly P., Cannom D., Garan H., Mirabal G., Harthorne W., The automatic implantable cardioverter defibrillator: Efficacy, complications and survival in patients with malignant ventricular arrhythmias, J Am Coll Cardiol, 11, pp. 1278-1286, (1988)

← 1 2 3 4 →